← Back to Search

Anti-mitotic Agent

Paclitaxel for Peripheral Arterial Disease (PacTAP Trial)

N/A
Waitlist Available
Led By Eric J Dippel, MD
Research Sponsored by Midwest Cardiovascular Research Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 and 12 months
Awards & highlights

PacTAP Trial Summary

The purpose of this study is to assess the safety and efficacy of administering intra-arterial paclitaxel in the femoropopliteal arteries via the TAPAS catheter following percutaneous revascularization to prevent restenosis.

Eligible Conditions
  • Peripheral Arterial Disease
  • Restenosis

PacTAP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Patency
Primary Safety
Secondary outcome measures
Functional Status
Primary Assisted Patency
Primary Patency at 12 months
+2 more

PacTAP Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: PaclitaxelActive Control1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Midwest Cardiovascular Research FoundationLead Sponsor
5 Previous Clinical Trials
224 Total Patients Enrolled
3 Trials studying Peripheral Arterial Disease
136 Patients Enrolled for Peripheral Arterial Disease
Spectranetics CorporationIndustry Sponsor
25 Previous Clinical Trials
4,342 Total Patients Enrolled
15 Trials studying Peripheral Arterial Disease
4,055 Patients Enrolled for Peripheral Arterial Disease
Eric J Dippel, MDPrincipal InvestigatorMidwest Cardiovascular Research Foundation
1 Previous Clinical Trials
252 Total Patients Enrolled
1 Trials studying Peripheral Arterial Disease
252 Patients Enrolled for Peripheral Arterial Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
New England Journal of MedicineJournal
Local Delivery of Paclitaxel to Inhibit Restenosis During Angioplasty of the Leg
Tepe, Gunnar, Thomas Zeller, Thomas Albrecht, Stephan Heller, Uwe Schwarzwälder, Jean-Paul Beregi, M.D. Claus D. Claussen, Anja Oldenburg, Bruno Scheller, and Ulrich Speck. 2008. “Local Delivery of Paclitaxel to Inhibit Restenosis During Angioplasty of the Leg”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmoa0706356.
CirculationJournal
Inhibition of Restenosis in Femoropopliteal Arteries
Werk, Michael, Soenke Langner, Bianka Reinkensmeier, Hans-Frank Boettcher, Gunnar Tepe, Ulrich Dietz, Norbert Hosten, Bernd Hamm, Ulrich Speck, and Jens Ricke. 2008. “Inhibition of Restenosis in Femoropopliteal Arteries”. Circulation. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/circulationaha.107.735985.
clinicaltrials.govStudy
Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention
Eric J Dippel, MD 2012. "Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01599078.
All > Acl
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top